Opendata, web and dolomites

kINPen

Developing a high-innovative portable cold plasma device for efficient healing of chronic wounds in veterinary medicine

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 kINPen project word cloud

Explore the words cloud of the kINPen project. It provides you a very rough idea of what is the project "kINPen" about.

calculated    gas    600    sales    infection    wounds    portable    reachable    months    healing    kinpen    uses    microorganism    pharmacological    farm    safe    price    health    sustainable    treatments    900    successfully    network    plasma    antibiotics    species    resistance    accelerates    overconsumption    time    revolutionize    investment    ca    innovative    ionized    rising    regional    stimulation    device    effect    50    veterinary    multidrug    share    microorganisms    radicals    generate    unpleasant    market    uv    neoplas    antibiotic    forming    ions    area    equals    antiviral    technologies    suppliers    fungi    wound    million    feeling    antifungal    950    revenues    animals    turnover    resistant    first    medical    stimulates    reg    presenting    ultrasound    physiological    18    pet    100    chronic    electrical    obtaining    opportunity    treatment    farming    segments    approximate    cold    110    electrons    radiation    wellbeing    manoeuvrable    laser    bacteria    led    advantages    urgently    anti    vet    costumers    constitutes    antimicrobial    efficient    organic    animal    electromagnetic    excited    surface    country    commercialization    inflammatory    return   

Project "kINPen" data sheet

The following table provides information about the project.

Coordinator
NEOPLAS GMBH 

Organization address
address: WALTHER RATHENAU STRASSE 49A
city: GREIFSWALD
postcode: 17489
website: www.neoplas.de

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Project website https://www.neoplas.eu/en/veterinarymedicine.html
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-01-01   to  2019-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    NEOPLAS GMBH DE (GREIFSWALD) coordinator 50˙000.00

Map

 Project objective

The veterinary sector urgently needs to revolutionize their treatment methods in order to solve the present antibiotic overconsumption and related growing resistance. This constitutes an important market opportunity for new technologies. Current non-pharmacological infection treatments such as ultrasound, electrical stimulation, laser or LED, are less efficient, given their cost, unpleasant feeling, treatment-time or required area. Therefore, neoplas GmbH successfully developed kINPen®VET, a non-pharmacological, high-innovative and portable cold plasma device for efficient healing of chronic wounds in farm and pet animals. It stimulates and accelerates physiological wound healing and is highly effective against typical wound bacteria, multidrug-resistant microorganisms and fungi, obtaining antiviral, antimicrobial, antifungal and anti-inflammatory effects on the treated surface without the need of antibiotics or developing microorganism resistance. It is based on cold plasma and uses the advantages of the Plasma Effect (ionized gas, electrons and ions, as well as radicals, excited species, UV radiation and electromagnetic fields). KINPen®VET will provide a 100% safe and manoeuvrable device, leading to a more cost-effective and sustainable veterinary medical treatment. kINPen®VET’s commercialization will generate high revenues in the targeted market segments of animal health and wellbeing and organic animal farming (market share 50%). This equals to an approximate number of more than 110.000 systems presenting a turnover of €950 million only in Europe. This ambitious target is reachable by forming a European network of regional suppliers, representatives and costumers in each targeted country. The production costs have been calculated with 5.900 €/ unit in the first 3 years and with a rising production the costs will be reduced to ca. 4.600 €/unit. The sales price is targeted with 8.900 €/unit and will allow a calculated return on investment in under 18 months.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "KINPEN" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "KINPEN" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

IMPACT (2019)

Improving DNA Analysis for Correct Healthcare

Read More  

Magnesys (2019)

Efficient filtering of metallic impurities in food processing

Read More  

LIVELMIA (2019)

Innovative assay for microRNAs analysis

Read More